Oruka Therapeutics (ORKA) Competitors

$68.95 +2.49 (+3.75%)

Closing price 04:00 PM Eastern

Extended Trading

$68.00 -0.95 (-1.37%)

As of 04:43 PM Eastern

ORKA vs. RDY, ELAN, ARWR, AXSM, and PRAX

Should you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Dr. Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), Axsome Therapeutics (AXSM), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does Oruka Therapeutics compare to Dr. Reddy's Laboratories?

Oruka Therapeutics (NASDAQ:ORKA) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

: 56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 24.7% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
: In the previous week, Oruka Therapeutics had 19 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 23 mentions for Oruka Therapeutics and 4 mentions for Dr. Reddy's Laboratories. Oruka Therapeutics' average media sentiment score of 0.74 beat Dr. Reddy's Laboratories' score of 0.42 indicating that Oruka Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oruka Therapeutics
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Dr. Reddy's Laboratories
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Oruka Therapeutics presently has a consensus price target of $120.80, indicating a potential upside of 75.20%. Dr. Reddy's Laboratories has a consensus price target of $16.90, indicating a potential upside of 27.40%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Oruka Therapeutics is more favorable than Dr. Reddy's Laboratories.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oruka Therapeutics
1 Sell rating(s)
0 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.82
Dr. Reddy's Laboratories
1 Sell rating(s)

2 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Oruka Therapeutics has a beta of -0.2, meaning that its share price is 120% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.
: Dr. Reddy's Laboratories has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oruka Therapeutics N/A N/A -$105.43M -$1.86 N/A
Dr. Reddy's Laboratories $3.81B 2.91 $663M $0.77 17.23
: Dr. Reddy's Laboratories has a net margin of 16.41% compared to Oruka Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 15.89% beat Oruka Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Oruka Therapeutics N/A -25.48% -24.34%
Dr. Reddy's Laboratories 16.41% 15.89% 10.73%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.86	N/A
Dr. Reddy's Laboratories	$3.81B	2.91	$663M	$0.77	17.23

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-25.48%	-24.34%
Dr. Reddy's Laboratories	16.41%	15.89%	10.73%

Summary

Dr. Reddy's Laboratories beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Oruka Therapeutics compare to Elanco Animal Health?

Oruka Therapeutics (NASDAQ:ORKA) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

: 56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 24.7% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: In the previous week, Oruka Therapeutics had 15 more articles in the media than Elanco Animal Health. MarketBeat recorded 23 mentions for Oruka Therapeutics and 8 mentions for Elanco Animal Health. Oruka Therapeutics' average media sentiment score of 0.74 beat Elanco Animal Health's score of 0.44 indicating that Oruka Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oruka Therapeutics
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Elanco Animal Health
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Oruka Therapeutics currently has a consensus price target of $120.80, indicating a potential upside of 75.20%. Elanco Animal Health has a consensus price target of $27.90, indicating a potential upside of 21.05%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Oruka Therapeutics is more favorable than Elanco Animal Health.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oruka Therapeutics
1 Sell rating(s)
0 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.82
Elanco Animal Health
1 Sell rating(s)

2 Hold rating(s)

9 Buy rating(s)

1 Strong Buy rating(s)
2.77
: Oruka Therapeutics has a beta of -0.2, meaning that its stock price is 120% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.
: Oruka Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oruka Therapeutics N/A N/A -$105.43M -$1.86 N/A
Elanco Animal Health $4.72B 2.43 -$232M -$0.48 N/A
: Oruka Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.92%. Elanco Animal Health's return on equity of 7.16% beat Oruka Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Oruka Therapeutics N/A -25.48% -24.34%
Elanco Animal Health -4.92% 7.16% 3.53%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.86	N/A
Elanco Animal Health	$4.72B	2.43	-$232M	-$0.48	N/A

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-25.48%	-24.34%
Elanco Animal Health	-4.92%	7.16%	3.53%

Summary

Oruka Therapeutics beats Elanco Animal Health on 9 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

: Arrowhead Pharmaceuticals has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arrowhead Pharmaceuticals $829.45M 12.65 -$1.63M $1.53 48.97
Oruka Therapeutics N/A N/A -$105.43M -$1.86 N/A
: In the previous week, Oruka Therapeutics had 6 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 23 mentions for Oruka Therapeutics and 17 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.81 beat Oruka Therapeutics' score of 0.74 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arrowhead Pharmaceuticals
6 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Oruka Therapeutics
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
: 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Arrowhead Pharmaceuticals currently has a consensus price target of $84.20, indicating a potential upside of 12.37%. Oruka Therapeutics has a consensus price target of $120.80, indicating a potential upside of 75.20%. Given Oruka Therapeutics' higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Arrowhead Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arrowhead Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.83
Oruka Therapeutics
1 Sell rating(s)

0 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.82
: Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.2, meaning that its share price is 120% less volatile than the S&P 500.
: Arrowhead Pharmaceuticals has a net margin of 18.54% compared to Oruka Therapeutics' net margin of 0.00%. Arrowhead Pharmaceuticals' return on equity of 35.64% beat Oruka Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Arrowhead Pharmaceuticals 18.54% 35.64% 13.61%
Oruka Therapeutics N/A -25.48% -24.34%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.65	-$1.63M	$1.53	48.97
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.86	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	6 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	18.54%	35.64%	13.61%
Oruka Therapeutics	N/A	-25.48%	-24.34%

Summary

Arrowhead Pharmaceuticals beats Oruka Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

: Axsome Therapeutics currently has a consensus price target of $251.89, indicating a potential upside of 12.93%. Oruka Therapeutics has a consensus price target of $120.80, indicating a potential upside of 75.20%. Given Oruka Therapeutics' higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Axsome Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
1 Sell rating(s)
1 Hold rating(s)

18 Buy rating(s)

1 Strong Buy rating(s)
2.90
Oruka Therapeutics
1 Sell rating(s)

0 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.82
: Oruka Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -28.69%. Oruka Therapeutics' return on equity of -25.48% beat Axsome Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics -28.69% -232.61% -25.84%
Oruka Therapeutics N/A -25.48% -24.34%
: Axsome Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.2, indicating that its stock price is 120% less volatile than the S&P 500.
: In the previous week, Axsome Therapeutics had 21 more articles in the media than Oruka Therapeutics. MarketBeat recorded 44 mentions for Axsome Therapeutics and 23 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.74 beat Axsome Therapeutics' score of 0.38 indicating that Oruka Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Axsome Therapeutics
13 Very Positive mention(s)
11 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Oruka Therapeutics
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
: 81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 22.3% of Axsome Therapeutics shares are held by insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Oruka Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Axsome Therapeutics $638.50M 17.97 -$183.17M -$3.69 N/A
Oruka Therapeutics N/A N/A -$105.43M -$1.86 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-28.69%	-232.61%	-25.84%
Oruka Therapeutics	N/A	-25.48%	-24.34%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	13 Very Positive mention(s)	11 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Oruka Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.97	-$183.17M	-$3.69	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.86	N/A

Summary

Oruka Therapeutics beats Axsome Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Oruka Therapeutics (NASDAQ:ORKA) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

: Oruka Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Praxis Precision Medicines N/A N/A -$303.27M -$13.46 N/A
Oruka Therapeutics N/A N/A -$105.43M -$1.86 N/A
: 67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Praxis Precision Medicines has a beta of 2.76, indicating that its share price is 176% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.2, indicating that its share price is 120% less volatile than the S&P 500.
: Praxis Precision Medicines currently has a consensus price target of $590.78, indicating a potential upside of 77.25%. Oruka Therapeutics has a consensus price target of $120.80, indicating a potential upside of 75.20%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, equities analysts plainly believe Praxis Precision Medicines is more favorable than Oruka Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Praxis Precision Medicines
2 Sell rating(s)
1 Hold rating(s)

12 Buy rating(s)

5 Strong Buy rating(s)
3.00
Oruka Therapeutics
1 Sell rating(s)

0 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.82
: Oruka Therapeutics' return on equity of -25.48% beat Praxis Precision Medicines' return on equity.
Company Net Margins Return on Equity Return on Assets
Praxis Precision Medicines N/A -58.74% -53.54%
Oruka Therapeutics N/A -25.48% -24.34%
: In the previous week, Oruka Therapeutics had 16 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 23 mentions for Oruka Therapeutics and 7 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.10 beat Oruka Therapeutics' score of 0.74 indicating that Praxis Precision Medicines is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Praxis Precision Medicines
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oruka Therapeutics
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.46	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.86	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.00
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-58.74%	-53.54%
Oruka Therapeutics	N/A	-25.48%	-24.34%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Praxis Precision Medicines beats Oruka Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Oruka Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORKA vs. The Competition

Export

Metric	Oruka Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.46B	$3.10B	$6.25B	$11.87B
Dividend Yield	N/A	1.91%	2.73%	5.21%
P/E Ratio	-37.07	18.37	29.03	28.47
Price / Sales	N/A	281.03	476.10	60.92
Price / Cash	N/A	50.43	27.62	36.52
Price / Book	7.12	4.33	9.67	6.67
Net Income	-$105.43M	$72.19M	$3.55B	$332.53M
7 Day Performance	-6.81%	2.02%	1.75%	2.03%
1 Month Performance	29.34%	6.41%	5.66%	9.23%
1 Year Performance	590.88%	37.69%	34.42%	39.62%

Oruka Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORKA Oruka Therapeutics	3.2351 of 5 stars	$68.95 +3.7%	$120.80 +75.2%	N/A	$3.46B	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	3.6476 of 5 stars	$13.67 +0.7%	$16.90 +23.6%	N/A	$11.33B	$3.81B	17.75	27,811	Upcoming Earnings
ELAN Elanco Animal Health	3.2666 of 5 stars	$22.76 +1.6%	$27.90 +22.6%	N/A	$11.13B	$4.72B	N/A	9,400	Upcoming Earnings
ARWR Arrowhead Pharmaceuticals	2.6361 of 5 stars	$73.91 -0.7%	$83.78 +13.4%	N/A	$10.42B	$1.09B	48.31	400	News Coverage Upcoming Earnings
AXSM Axsome Therapeutics	3.1782 of 5 stars	$185.96 +1.8%	$218.06 +17.3%	N/A	$9.35B	$638.50M	N/A	380	Trending News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORKA) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oruka Therapeutics (ORKA) Competitors

ORKA vs. RDY, ELAN, ARWR, AXSM, and PRAX

How does Oruka Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Oruka Therapeutics compare to Elanco Animal Health?

Summary

How does Oruka Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Oruka Therapeutics compare to Axsome Therapeutics?

Summary

How does Oruka Therapeutics compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oruka Therapeutics (ORKA) Competitors

ORKA vs. RDY, ELAN, ARWR, AXSM, and PRAX

How does Oruka Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Oruka Therapeutics compare to Elanco Animal Health?

Summary

How does Oruka Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Oruka Therapeutics compare to Axsome Therapeutics?

Summary

How does Oruka Therapeutics compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools